/MSCLF
MSCLF Stock - Satellos Bioscience Inc.
Healthcare|BiotechnologyOTC
$0.48-2.24%
$0.01 (-2.24%) • Dec 19
63
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.39
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.91
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.53
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MSCLF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.48 – $0.48
TARGET (TP)$0.55
STOP LOSS$0.44
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.71
52W High$0.66
52W Low$0.38
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-19,603 | $-8,817 | $-336,948 | $-119,919 | $-48,161 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-27,808 | $-15,463 | $-8,406,661 | $-4,736,736 | $-1,545,248 |
| Net Income | $-28,099 | $-15,889 | $-11,322,437 | $-15,505,652 | $-1,578,530 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.24 | $-0.18 | $-0.32 | $-0.64 | $-0.05 |
Company Overview
Satellos Bioscience Inc., a regenerative medicine company, develops therapeutics to treat degenerative muscle diseases. Its lead program focuses on the development of oral therapeutic drug to correct muscle stem cell polarity and restore the body's innate muscle repair and regeneration process. The company was incorporated in 2012 and is headquartered in Toronto, Canada.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
MSCLFBeat Rate
38%
Last 13 quarters
Avg Surprise
-19.3%
EPS vs Estimate
Beats / Misses
5/7
1 met exactly
Latest EPS
$-0.03
Q4 2025
EPS Surprise History
Q1 24
-300.0%
$-0.04vs$-0.01
Q2 24
-8.4%
$-0.04vs$-0.04
Q3 24
+20.0%
$-0.04vs$-0.05
Q4 24
-20.0%
$-0.06vs$-0.05
Q1 25
+80.0%
$-0.01vs$-0.05
Q2 25
-27.2%
$-0.04vs$-0.03
Q3 25
+10.6%
$-0.02vs$-0.02
Q4 25
-10.3%
$-0.03vs$-0.03
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 14, 2025 | $-0.03 | $-0.03 | -10.3% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-0.02 | $-0.02 | +10.6% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.03 | $-0.04 | -27.2% | ✗ MISS |
Q1 2025 | Mar 26, 2025 | $-0.05 | $-0.01 | +80.0% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-0.05 | $-0.06 | -20.0% | ✗ MISS |
Q3 2024 | Aug 12, 2024 | $-0.05 | $-0.04 | +20.0% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-0.04 | $-0.04 | -8.4% | ✗ MISS |
Q1 2024 | Mar 27, 2024 | $-0.01 | $-0.04 | -300.0% | ✗ MISS |
Q4 2023 | Nov 22, 2023 | $-0.02 | $-0.02 | 0.0% | = MET |
Q3 2023 | Aug 28, 2023 | $-0.03 | $-0.04 | -33.3% | ✗ MISS |
Q2 2023 | May 30, 2023 | $-0.04 | $-0.03 | +25.0% | ✓ BEAT |
Q1 2023 | Mar 30, 2023 | $-0.09 | $-0.10 | -7.4% | ✗ MISS |
Q4 2022 | Nov 23, 2022 | $-0.05 | $-0.04 | +20.0% | ✓ BEAT |
Q3 2022 | Aug 29, 2022 | — | $-0.05 | — | — |
Q2 2022 | May 30, 2022 | — | $-0.05 | — | — |
Q2 2022 | Apr 29, 2022 | — | $-0.05 | — | — |
Q4 2021 | Nov 29, 2021 | — | $-0.34 | — | — |
Q3 2021 | Aug 31, 2021 | — | $-0.01 | — | — |
Q2 2021 | Apr 29, 2021 | — | — | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.02 | — | — |
Frequently Asked Questions about MSCLF
What is MSCLF's current stock price?
Satellos Bioscience Inc. (MSCLF) is currently trading at $0.48 per share. The stock has moved -2.24% today.
What is the analyst price target for MSCLF?
No analyst price targets are currently available for this stock.
What sector is Satellos Bioscience Inc. in?
Satellos Bioscience Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is MSCLF's market cap?
Satellos Bioscience Inc. has a market capitalization of $0.09 billion, making it a small-cap company.
Does MSCLF pay dividends?
No, Satellos Bioscience Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBSEM
BioStem Technologies, Inc.
$4.24
Mkt Cap: $0.1B
HSCHF
H-Source Holdings Ltd.
$0.00
Mkt Cap: $0.0B
IUGNF
Imugene Limited
$0.22
Mkt Cap: $0.1B
KNTPF
Kintor Pharmaceutical Limited
$0.22
Mkt Cap: $0.1B
PBIGF
Paradigm Biopharmaceuticals Limited
$0.23
Mkt Cap: $0.1B
POLBF
Poolbeg Pharma PLC
$0.04
Mkt Cap: $0.0B
PRNAF
Alterity Therapeutics Limited
$0.01
Mkt Cap: $0.1B
SPHRY
Starpharma Holdings Limited
$2.20
Mkt Cap: $0.1B
TOKIF
Optima Medical Innovations Corp.
$0.01
Mkt Cap: $0.1B
VSBC
VitaSpring Biomedical Co. Ltd.
$1.00
Mkt Cap: $0.2B
Explore stocks similar to MSCLF for comparison